Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/15772
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorOvejero Benito, María del Carmen-
dc.creatorPrieto Pérez, Rocío-
dc.creatorLlamas Velasco, Mar-
dc.creatorMuñoz Aceituno, Ester-
dc.creatorReolid, Alejandra-
dc.creatorSaiz Rodríguez, Miriam-
dc.creatorBelmonte, Carmen-
dc.creatorRomán, Manuel-
dc.creatorOchoa Mazarro, Dolores-
dc.creatorTalegón, María-
dc.creatorCabaleiro, Teresa-
dc.creatorDaudén, Esteban-
dc.creatorAbad-Santos, Francisco-
dc.date.accessioned2024-05-10T16:52:28Z-
dc.date.available2024-05-10T16:52:28Z-
dc.date.issued2017-12-01-
dc.identifier.citationOvejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Talegón M, Cabaleiro T, Daudén E, Abad-Santos F. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics. 2018 Jan;19(1):7-16. doi: 10.2217/pgs-2017-0143es_ES
dc.identifier.issn1744-8042-
dc.identifier.urihttp://hdl.handle.net/10637/15772-
dc.descriptionVersión en abierto siguiendo la política de la revistaes_ES
dc.description.abstractAims-. This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab. Materials and methods-. Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (N=95) and 6 months of treatment (N=90). Significant SNPs for univariate analysis were subjected to multivariate analysis. Results/Conclusions-. Five SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months. Nevertheless, these biomarkers should be validated in large-scale studies before implementation in clinical practice.es_ES
dc.formatapplication/pdf-
dc.language.isoenes_ES
dc.publisherFuture Medicinees_ES
dc.relation.ispartofPharmacogenomics-
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.es-
dc.subjectPsoriatic patientses_ES
dc.subjectPharmacogeneticses_ES
dc.titlePolymorphisms associated with adalimumab and infliximab response in moderate to-severe plaque psoriasises_ES
dc.typeArtículoes_ES
dc.identifier.doi10.2217/pgs-2017-0143-
dc.centroUniversidad San Pablo-CEU-
Aparece en las colecciones: Facultad de Farmacia




Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.